Eagle’s Eye View: More ESC 2025 Hot Trial Data
Dr. Eagle continues in this week’s View to analyze some of the key clinical content presented at the ESC Congress recently held in Spain. Dr. Eagle examines the TARGET-FIRST trial in which P2Y12-inhibitor monotherapy was compared to dual antiplatelet therapy (DAPT) in patients who have undergone percutaneous coronary intervention (PCI). He then analyzes the results of the ODYSSEY-HCM trial which explored mavacamten versus placebo in patients with symptomatic nonobstructive hypertrophic cardiomyopathy (HCM). Finally, Dr. Eagle discusses the ESSENCE-TIMI 73b study that looked at olezarsen and its potential for lowering triglycerides in moderate hypertriglyceridemia with elevated cardiovascular risk.
X Links:
- Kim Eagle, MD, MACC keaglemd
Clinical Topics: Acute Coronary Syndromes, Diabetes and Cardiometabolic Disease, Dyslipidemia, Heart Failure and Cardiomyopathies, Invasive Cardiovascular Angiography and Intervention, Prevention, Acute Heart Failure, Interventions and ACS, Interventions and Imaging, Interventions and Structural Heart Disease, Angiography, Nuclear Imaging, Noninvasive Imaging
Keywords: EaglesEyeView, ESC Congress, ESC25, Angiography, Acute Coronary Syndrome, Cardiomyopathy, Hypertrophic, Heart Failure, Secondary Prevention, Dyslipidemias
